Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 12/17/2024 | $12.00 → $13.00 | Underweight → Neutral | Analyst | |
| 12/13/2024 | $18.00 → $21.00 | Equal-Weight → Overweight | Morgan Stanley | |
| 12/9/2024 | $18.00 | Neutral → Buy | BofA Securities | |
| 10/7/2024 | $145.00 | Neutral → Outperform | Macquarie | |
| 7/22/2024 | $12.00 → $18.00 | Underperform → Neutral | BofA Securities | |
| 7/17/2024 | $27.00 | Outperform → Neutral | Robert W. Baird | |
| 7/10/2024 | $20.00 | Hold → Buy | Argus | |
| 6/24/2024 | $12.00 | Sell | Goldman |
GREEN BAY, Wis., Dec. 19, 2024 /PRNewswire/ -- Associated Banc-Corp (NYSE: ASB) ("Associated" or "Company") today announced the addition of four experienced relationship managers to the company's growing commercial banking team. The hiring of Stacy Quick, Kevin Kopaska, Mike Hauswirth and Scott Rothenbush is a continuation of Associated's multi-year strategic growth plan designed to bolster talent in key focus markets, expand commercial capabilities, and deepen relationships with new and existing clients. "We're thrilled to have Stacy, Kevin, Mike and Scott join our team as we
MILWAUKEE, Dec. 12, 2024 /PRNewswire/ -- Associated Banc-Corp (NYSE: ASB) ("Associated") announced today the appointment of Steven Zandpour to its Executive Leadership Team (ELT), effective January 1, 2025. Zandpour, 48 will be executive vice president, deputy head of Consumer and Business Banking, Associated Bank, reporting directly to David Stein, executive vice president, head of Consumer and Business Banking and Madison Market president. "Steve's people-first leadership style and dedication to colleagues and customers has helped us grow our business and improve our custome
Sorenson will transition into the role of executive vice president, managing director and CEO, Associated Trust Company on February 1, 2025 GREEN BAY, Wisc., Dec. 11, 2024 /PRNewswire/ -- Associated Banc-Corp (NYSE:ASB) ("Associated") announced today the appointment of Heath Sorenson, MBA, CFP®, CFIRS™, CTOP, to executive vice president, managing director, Associated Trust Company. Effective February 1, 2025, Sorenson will become executive vice president, managing director and chief executive officer, Associated Trust Company and John Thayer, current chief executive officer and executive vice president of Associated Trust Company, will transition into the role of executive vice president and
TaskUs, Inc. (NASDAQ:TASK), a leading provider of outsourced digital services and next-generation customer experience to the world's most innovative companies, will report its fourth-quarter and full-year 2024 financial results after the market closes on February 26, 2025. Simultaneous with the earnings release, supplemental data will be available on the Investor Relations section of TaskUs' website at https://ir.taskus.com under "News & Events." Management will host a conference call and webcast at 5:00 p.m. ET to discuss the company's business, financial results and 2025 outlook. Investors and other interested parties can access the call and webcast as noted below: What: TaskUs Fourth
Alibaba Group Holding Limited (NYSE: BABA and HKEX: 9988 (HKD Counter) and 89988 (RMB Counter), "Alibaba" or "Alibaba Group") today announced that it will report its unaudited financial results for the quarter ended December 31, 2024 before the U.S. market opens on Thursday, February 20, 2025, and will hold a conference call to discuss the financial results at 7:30 a.m. U.S. Eastern Time (8:30 p.m. Hong Kong Time) the same day. All participants must pre-register to join this conference call using the Participant Registration link below: English: https://s1.c-conf.com/diamondpass/10044500-45dty1.html Chinese: https://s1.c-conf.com/diamondpass/10044501-01fde1.html Upon registration, each
2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023;AUSTEDO® - exceeding $1.6 billion in revenues, surpassing 2024 outlook;AJOVY® - global annual revenues of $507 million, an increase of 18% in local currency terms compared to 2023;UZEDY® revenues of $117 million in 2024 surpassing $100M outlook;Generics business continues to grow across all segments, with increases of 15% in the U.S., 6% in Europe and 15% in International Markets, all in local currency terms compared to 2023;First-to-market launches including first generic version of Sandostatin® LAR Depot and liraglutide injection 1.8mg (an authorized generic of Victoza®); On January 2025, Te
TaskUs, Inc. (NASDAQ:TASK), a leading provider of outsourced digital services and next-generation customer experience to the world's most innovative companies, will report its fourth-quarter and full-year 2024 financial results after the market closes on February 26, 2025. Simultaneous with the earnings release, supplemental data will be available on the Investor Relations section of TaskUs' website at https://ir.taskus.com under "News & Events." Management will host a conference call and webcast at 5:00 p.m. ET to discuss the company's business, financial results and 2025 outlook. Investors and other interested parties can access the call and webcast as noted below: What: TaskUs Fourth
Alibaba Group Holding Limited (NYSE: BABA and HKEX: 9988 (HKD Counter) and 89988 (RMB Counter), "Alibaba" or "Alibaba Group") today announced that it will report its unaudited financial results for the quarter ended December 31, 2024 before the U.S. market opens on Thursday, February 20, 2025, and will hold a conference call to discuss the financial results at 7:30 a.m. U.S. Eastern Time (8:30 p.m. Hong Kong Time) the same day. All participants must pre-register to join this conference call using the Participant Registration link below: English: https://s1.c-conf.com/diamondpass/10044500-45dty1.html Chinese: https://s1.c-conf.com/diamondpass/10044501-01fde1.html Upon registration, each
2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023;AUSTEDO® - exceeding $1.6 billion in revenues, surpassing 2024 outlook;AJOVY® - global annual revenues of $507 million, an increase of 18% in local currency terms compared to 2023;UZEDY® revenues of $117 million in 2024 surpassing $100M outlook;Generics business continues to grow across all segments, with increases of 15% in the U.S., 6% in Europe and 15% in International Markets, all in local currency terms compared to 2023;First-to-market launches including first generic version of Sandostatin® LAR Depot and liraglutide injection 1.8mg (an authorized generic of Victoza®); On January 2025, Te
SCHEDULE 13G/A - Clene Inc. (0001822791) (Subject)
SCHEDULE 13G/A - Clene Inc. (0001822791) (Subject)
13F-HR - Alibaba Group Holding Ltd (0001577552) (Filer)
Analyst upgraded Bioventus from Underweight to Neutral and set a new price target of $13.00 from $12.00 previously
Morgan Stanley upgraded TaskUs from Equal-Weight to Overweight and set a new price target of $21.00 from $18.00 previously
BofA Securities upgraded TaskUs from Neutral to Buy and set a new price target of $18.00
SC 13G/A - Alibaba Group Holding Ltd (0001577552) (Filed by)
SC 13G/A - Clene Inc. (0001822791) (Subject)
SC 13G - Clene Inc. (0001822791) (Subject)
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)